Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Rectal Cancer

April 27, 2020

Advances in the Treatment of Locally Advanced or Metastatic Rectal Cancer
The determination of an optimal treatment plan for patients with rectal cancer is a complex process that is reliant on balancing the potential risks and benefits of each treatment option based on an individual patient’s characteristics. Clinicians must be educated about on emerging approaches to personalized treatment for patients with rectal cancer so that the most appropriate treatment option(s) can be offered to each patient. As several of the checkpoint inhibitors have been recently approved for treatment of dMMR/MSI-H metastatic rectal cancer, discussion of the immune-related adverse effects associated with these therapies would be relevant.

Target Audience

This program is designed to meet the educational needs of physicians, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Identify emerging treatment approaches for locally advanced rectal cancer that may reduce morbidity for certain patients.
  • Describe the total neoadjuvant therapy approach for treatment of rectal cancer, including the benefits and drawbacks of this approach.
  • Discuss recently approved systemic therapy options for metastatic rectal cancer, including how biomarker testing can guide selection of appropriate treatment in this setting.
Additional information
Supporters: 

This activity is supported by an educational grant from:

  • AstraZeneca
  • Celgene Corporation
  • Clovis Oncology, Inc.
  • Eisai
  • Genomic Health, Inc.
  • Lilly
  • Novartis
  • Sanofi Genzyme
  • Taiho Oncology, Inc
  • TESARO

This activity is supported by an independent medical education grant from:

  • Advanced Accelerator Applications, a Novartis company
  • Bristol-Myers Squibb
  • Pharmacyclics LLC and Janssen

This activity is supported by an independent educational grant from:

  • AbbVie
  • Astellas and Pfizer, Inc.
  • Merck  & Co., Inc.

This activity is supported by a medical education grant from Exelixis, Inc.

This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
03/02/2020
Course expires: 
07/12/2020
Event starts: 
04/27/2020 - 3:30pm
Event ends: 
04/27/2020 - 4:30pm
Cost:
$0.00

Karyn A. Goodman, MD
The Tisch Cancer Institute

Wells A. Messersmith, MD
University of Colorado Cancer Center

Jon Vogel, MD
University of Colorado Cancer Center

 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Full disclosure of faculty relationships will be made prior to the activity.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-20-039-L01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. Credit approval for case managers is pending for this program.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to register for this live webinar.

This webinar will be presented live one time only on Monday, April 27, 2020, from 3:30 - 4:30 PM Eastern Daylight Time (EST) (UTC -4).  To adjust for other time zones, click here.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing